This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
Autoimmune diseases — in which the immune system attacks the body's own tissues — collectively affect approximately 50 million Americans and represent a major area of clinical trial activity. In 2026, the most transformative development is the emergence of CAR-T cell therapy achieving drug-free remission in systemic lupus erythematosus and other severe autoimmune diseases. Beyond this breakthrough, TYK2 inhibitors, bispecific antibodies, and next-generation biologics are expanding treatment options for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and multiple sclerosis.
CAR-T Cell Therapy: A Paradigm Shift in Autoimmunity
The most dramatic autoimmunity result of 2024–2026 is the use of anti-CD19 CAR-T cell therapy to achieve drug-free remission in severe refractory autoimmune diseases. Published in Nature Medicine (Mackensen et al., 2022, updated in 2024–2025), 15 patients with severe SLE, myositis, systemic sclerosis, and other refractory autoimmune conditions received a single infusion of autologous anti-CD19 CAR-T cells. The results were extraordinary: patients achieved clinical remission and could stop all other immunosuppressive medications, with follow-up now exceeding 2 years in the earliest patients with sustained remission. One patient with SLE who had been on 10 medications was completely off all therapy and in deep remission at 18 months.
The mechanism involves depleting the pathological B cell clones driving autoimmunity, followed by reconstitution from naive B cell precursors that lack the autoreactive specificities — effectively resetting the immune system. Phase 2 trials (RESET-SLE, RESCUE-myositis, CAR-T for systemic sclerosis) are now enrolling at Erlangen, Stanford, Johns Hopkins, and University of Pennsylvania. The key eligibility criterion is severe refractory disease — having failed at least two biologic or immunosuppressive therapies — and the procedure is currently available only at specialized centers with CAR-T manufacturing capabilities.
Rheumatoid Arthritis: TYK2 Inhibitors and Bispecific Antibodies
Rheumatoid arthritis (RA) has an established armamentarium of DMARDs (methotrexate), biologics (TNF inhibitors, IL-6 inhibitors, abatacept, rituximab), and JAK inhibitors (tofacitinib, baricitinib, upadacitinib). Despite this, 20–30% of patients do not achieve sustained remission with any available therapy. TYK2 inhibitors — deucravacitinib (already approved for psoriasis) and other TYK2-selective agents — are being evaluated in RA Phase 2/3 trials, offering a potentially safer alternative to JAK1/2/3 inhibitors (which carry cardiovascular and malignancy warnings from the ORAL Surveillance trial with tofacitinib).
Bispecific antibodies targeting two immune pathways simultaneously — obexelimab (anti-CD19/anti-FcγRIIb, targeting B cell and immune complex activation) in Phase 3 for RA, and izokibep (IL-17A inhibitor bispecific) — are the next generation of RA biologics. Drug-free remission trials — testing whether patients with established biologic remission can successfully discontinue therapy (AVERT, RETRO, SPARE) — are addressing a critical patient priority: can we ever safely stop biologics after achieving remission? Preliminary data suggest ~25–35% of patients who discontinue in sustained remission remain remission-free at 1 year, with clinical and biomarker predictors of success under investigation.
Lupus: New Biologics and Emerging Therapies
Systemic lupus erythematosus (SLE) has seen significant recent advances: anifrolumab (Saphnelo, type I interferon receptor antibody) achieved FDA approval in 2021 for moderate-to-severe SLE, and the TULIP-1 and TULIP-2 trials established it as the most effective SLE biologic for skin and musculoskeletal disease. Voclosporin (Lupkynis) and belimumab are now both approved for lupus nephritis. In 2026, trials are focused on: telitacicept (BlyS/APRIL dual inhibitor, RemeGen), which showed a 79% SRI-4 response rate in Phase 2 Chinese trials, is in Phase 3 in the US and Europe; anifrolumab extended dosing intervals; and combination biologic approaches for refractory nephritis.
Ianalumab (anti-BAFF receptor antibody, Novartis) is in Phase 3 SIRIUS trial for SLE, and obinutuzumab (anti-CD20, Roche) is in Phase 3 for lupus nephritis after superior efficacy vs. mycophenolate in Phase 2. The LUNAR program for atorolimumab (anti-CD40L) failed due to thrombosis, but next-generation CD40L-targeting agents with engineered Fc regions to avoid thrombotic risk (frexalimab, tegoprubart) are in Phase 2 for SLE and other autoimmune conditions based on the hypothesis that CD40/CD40L blockade targets the core T-B cell interaction driving autoimmunity.
Multiple Sclerosis and Inflammatory Bowel Disease Highlights
Multiple sclerosis (MS) BTK inhibitor trials (tolebrutinib HERCULES showing efficacy in progressive MS for the first time) are covered in depth in the Neurology article. In IBD (Crohn's and UC), the major 2026 trial activity is combination biologic therapy: VEGA Phase 2 established that guselkumab (anti-IL-23) plus golimumab (anti-TNF) produced significantly higher remission rates than either alone in UC — a paradigm shift toward combination immunotherapy for IBD. The EXPLORER Phase 3 combination trial is now enrolling. JAK inhibitors (upadacitinib, filgotinib) are expanding into Crohn's disease with Phase 3 results expected, and S1P receptor modulators (etrasimod, ozanimod) are establishing the oral alternative to biologic therapy for UC.
Atopic dermatitis, psoriasis, and asthma trials continue to generate data on IL-4/13, IL-17, IL-23, and thymic stromal lymphopoietin (TSLP) targeting — with dupilumab's extraordinary breadth of effect (eczema, asthma, CRSwNP, eosinophilic esophagitis, COPD) establishing the IL-4/IL-13 axis as arguably the most important cytokine node in allergic/eosinophilic disease. Itepekimab (anti-IL-33), tezepelumab (anti-TSLP), and lebrikizumab (anti-IL-13) are completing Phase 3 programs across this disease spectrum.
How to Find Autoimmune Disease Trials
Rheumatology, gastroenterology, dermatology, and neurology practices are the primary sites for autoimmune disease trials. Academic medical centers with comprehensive autoimmune disease programs (Johns Hopkins, Mayo Clinic, UCSF, Northwestern, Columbia, Hospital for Special Surgery) have the largest trial portfolios. ClinicalTrials.gov searches by specific diagnosis filtered to "Recruiting" yield disease-specific results; the ACR (American College of Rheumatology) and Arthritis Foundation maintain patient-facing trial information. For SLE and inflammatory myopathies, the Lupus Research Alliance (lupusresearch.org) and Myositis Association (myositis.org) provide disease-specific trial listings and patient navigators.
Key Takeaways
- Anti-CD19 CAR-T cell therapy is producing drug-free remission in severe refractory SLE, myositis, and systemic sclerosis — Phase 2 trials (RESET-SLE, RESCUE) are enrolling at specialized centers for patients who have failed multiple biologics.
- TYK2 inhibitors are in Phase 3 for RA as potentially safer JAK inhibitor alternatives; bispecific antibodies (obexelimab) targeting dual B cell activation pathways are in Phase 3.
- VEGA Phase 2 established that guselkumab plus golimumab combination biologic therapy produces higher UC remission than either monotherapy — Phase 3 EXPLORER combination trials are now enrolling, potentially redefining IBD treatment standards.
- Telitacicept (BlyS/APRIL dual inhibitor) is in Phase 3 for SLE after exceptional Phase 2 Chinese trial results; frexalimab and tegoprubart (safer CD40L blockers) are in Phase 2 targeting the core T-B interaction in autoimmunity.
- Drug-free remission trials for RA (AVERT, RETRO, SPARE) show ~25–35% of patients in biologic remission remain remission-free after discontinuation — clinical and biomarker predictors are being characterized to identify who can safely stop treatment.